All projects with ATG are scientific collaborations. We will work together with the applicant’s team on experimental design, workflow adaptation, material and data handling and budgeting. ATG will cover the operational costs to successfully complete the project. Applicants will be responsible for reagent and consumable costs. The goal for the ATG team is to collaborate on joint publications and protection of technological and scientific advances enabled by the ATG by joint patent filings as appropriate. Whenever possible we envision publishing in open source journals and making cell lines available to the research community as soon as possible after they are generated.

All proposals will be reviewed by a multidisciplinary review committee and evaluated based on the compatibility and availability of ATTIS and the ATG team, and the overall alignment with the IGI’s mission to improve human health. Previous experience with the handling of human pluripotent stem cells (induced pluripotent stem cells or human embryonic stem cells) is required. Projects are performed as collaboration and laboratories need to be able to adequately maintain the returned hPSCs, process the genetic material, and analyze the genetic data as it fits into the agreed upon collaboration.

During the project collecting period (March and September when the capacity allows), collaborators are welcome to submit the mutations (at most 2 per lab) they want to have as isogenic hPSCs. The ATG team will handle the entire genome editing process, including editing strategy design, tissue culture, and genotyping. We will cover the operational cost while the reagent cost will rely on the collaborator labs.

SUBMIT A REQUEST